Status:
COMPLETED
The Influence Factors of Bispectral Index Values Increment Caused by Sugammadex
Lead Sponsor:
Jun Zhang
Conditions:
BIS
Eligibility:
All Genders
18-80 years
Brief Summary
Sugammadex administration may increase the bispectral index (BIS) values during general anesthesia. The purpose of this study was to investigate the influence factors leading to increase in BIS value ...
Detailed Description
Sugammadex administration may increase the bispectral index (BIS) values during general anesthesia. The purpose of this study was to investigate the influence factors leading to increase in BIS value ...
Eligibility Criteria
Inclusion
- Patients with American Society of Anesthesiologists (ASA) physical status Ⅰ - Ⅱ scheduled for elective surgery who agreed to participate and who signed the informed consent were included. Other inclusion criteria were age between 18 and 80 years and scheduled for elective non-cardiothoracic and non-neurological cancer surgery under general anesthesia (GA)
Exclusion
- Known hypersensitivity to sugammadex; severe renal insufficiency (creatinine clearance \< 30 ml.min-1); treatment with toremifene, flucloxacillin or fusidic acid in the pre-operative or immediate postoperative period; and neuropsychiatric disorders or treatment with a psychotropic agent.
Key Trial Info
Start Date :
August 20 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 14 2024
Estimated Enrollment :
135 Patients enrolled
Trial Details
Trial ID
NCT06561633
Start Date
August 20 2024
End Date
September 14 2024
Last Update
September 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032